The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Predictive biomarkers of response to VenBd in R/R MM
Michael O’Dwyer, MD, PhD, National University of Ireland, Galway, Ireland, discusses the biomarker analysis from the phase III BELLINI study (NCT02755597) of venetoclax in combination with bortezomib and dexamethasone (VenBd) in patients with relapsed/refractory (R/R) multiple myeloma (MM). This revealed that VenBd shows significant efficacy in patients harboring either t(11;14) or with tumor cells expressing high levels of BCL2. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
